{
    "name": "immune globulin SC",
    "comment": "Rx",
    "other_names": [
        "Hizentra",
        "HyQvia",
        "Cuvitru",
        "Gammagard Liquid SC",
        "Gamunex-C SC",
        "Cutaquig",
        "Xembify",
        "immune globulin SC-klhw"
    ],
    "classes": [
        "Immune Globulins"
    ],
    "source": "https://reference.medscape.com/drug/hizentra-cutaquig-immune-globulin-sc-343219",
    "pregnancy": {
        "common": [
            "No human data are available to indicate the presence or absence of drug-associated risk",
            "Unknown whether immune globulin SC can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity",
            "Immune globulins cross the placenta from maternal circulation increasingly after 30 weeks of gestation; therefore, drug should be given to pregnant women only if clearly needed"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "No human data are available to indicate the presence or absence of drug-associated risk",
            "Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for immune globulin SC and any potential adverse effects on the breastfed infant from immune globulin SC or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Thrombosis",
                    "description": [
                        "Thrombosis may occur with immune globulin products",
                        "Risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, history of thrombosis, estrogen use, indwelling central vascular catheters, hyperviscosity, and CV risk factors",
                        "For at risk patients, use lowest possible dose and infusion rate, ensure adequate hydration before administration, assess blood viscosity, and monitor for signs and symptoms of thrombosis"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to immune globulins or solution components",
                "IgA-deficiency with antibodies against IgA and history of hypersensitivity",
                "Hyperprolinemia Type I or II"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Infusion into or around an infected area can spread a localized infection; do not infuse HyQvia into these areas due to potential risk of spreading a localized infection Initial treatment should be done in clinical setting (due to possibility of anaphylactic reactions)",
                "Subcutaneous administration associated with increased risk of hematoma",
                "Hyperproteinemia and hyponatremia may occur",
                "In clinical studies, eighteen percent of subjects receiving HyQvia developed non-neutralizing antibodies to the recombinant human hyaluronidase component; potential exists for such antibodies to cross-react with endogenous PH20, which is known to be expressed in the adult male testes, epididymis, and sperm; unknown whether these antibodies may interfere with fertilization in humans or its clinical significance",
                "Because this product is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, theCreutzfeldt-Jakob disease (CJD) agent; this also applies to unknown or emerging viruses and other pathogens; no cases of transmission of viral diseases or CJD have been associated with this therapy; all infections suspected by a physician possibly to have been transmitted by this product should be reported to CSL Behring Pharmacovigilance at 1-866-915-6958"
            ],
            "specific": [
                {
                    "type": "Transfusion-related acute lung injury (TRALI)",
                    "description": [
                        "Noncardiogenic pulmonary edema may occur in patients administered human immune globulin products; TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever",
                        "Typically, it occurs within 1-6 hours following transfusion; patients with TRALI may be managed using oxygen therapy with adequate ventilatory support",
                        "Monitor therapy recipients for pulmonary adverse reactions; if TRALI suspected, perform appropriate tests for presence of anti-neutrophil antibodies in both the product and patient’s serum"
                    ]
                },
                {
                    "type": "Hypersensitivity",
                    "description": [
                        "Severe hypersensitivity reactions may occur, even in patients who have tolerated previous treatment with IgG",
                        "If a hypersensitivity reaction occurs, discontinue therapy immediately and institute appropriate treatment",
                        "Individuals with IgA deficiency can develop anti-IgA antibodies and anaphylactic reactions (including anaphylaxis and shock) after administration of blood components containing IgA",
                        "Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions with administration of this medication, which contains ≤50 mcg/mL IgA"
                    ]
                },
                {
                    "type": "Thrombosis",
                    "description": [
                        "Thrombosis may occur; risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors",
                        "Thrombosis may occur in absence of known risk factors;consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triglycerides, or monoclonal gammopathies",
                        "For patients at risk of thrombosis, administer at a minimum dose and infusion rate practicable; ensure adequate hydration in patients before administration",
                        "Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity"
                    ]
                },
                {
                    "type": "Aseptic meningitis syndrome (AMS)",
                    "description": [
                        "AMS reported with use of IGIV4 or IGSC; the syndrome usually begins within several hours to 2 days following immune globulin treatment; AMS is characterized by severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, and vomiting",
                        "Cerebrospinal fluid (CSF) studies frequently show pleocytosis up to several thousand cells per cubic millimeter, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dL; AMS may occur more frequently in association with high doses (≥2 g/kg) and/or rapid infusion of immune globulin product",
                        "Patients exhibiting such signs and symptoms should receive a thorough neurological examination, including CSF studies, to rule out other causes of meningitis; discontinuation of immune globulin treatment has resulted in remission of AMS within several days without sequelae"
                    ]
                },
                {
                    "type": "Renal dysfunction/failure",
                    "description": [
                        "Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with use of human immune globulin products, especially those containing sucrose; this product does not contain sucrose",
                        "Ensure that patients are not volume depleted before administering this product",
                        "For patients judged to be at risk for developing renal dysfunction, including patients with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs, monitor renal function and consider lower, more frequent dosing",
                        "Periodic monitoring of renal function and urine output is particularly important in patients judged to have a potential increased risk of developing acute renal failure; assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before initial infusion and at appropriate intervals thereafter; if renal function deteriorates, consider discontinuing therapy"
                    ]
                },
                {
                    "type": "Hemolysis",
                    "description": [
                        "This product can contain blood group antibodies that may act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin(Coombs’) test result and hemolysis",
                        "Delayed hemolytic anemia can develop subsequent to immune globulin therapy due to enhanced RBC sequestration, and acute hemolysis, consistent with intravascular hemolysis, reported",
                        "Monitor recipients of this therapy for clinical signs and symptoms of hemolysis; if signs and/or symptoms of hemolysis are present after infusion, perform appropriate confirmatory laboratory testing"
                    ]
                },
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "Live virus vaccines",
                        "Passive transfer of antibodies with immunoglobulin administration may interfere with response to live virus vaccines (eg, measles, mumps, rubella, varicella) HyQvia may impair immune response to live attenuated virus vaccines (eg, mumps, rubella, varicella) for up 6 months and for a year or more to measles",
                        "Interference with laboratory tests",
                        "Various passively transferred antibodies in immunoglobulin preparations may lead to misinterpretation of the results of serological testing",
                        "Passive transmission of antibodies to erythrocyte antigens (eg, A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs’) test",
                        "Administration of Cuvitru can lead to false positive readings in assays that depend on detection of beta-D-glucans for diagnosis of fungal infections; this may persist during the weeks following infusion of the product"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "immune globulin SC, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "immune globulin SC, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "immune globulin SC, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "immune globulin SC, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "immune globulin SC, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "immune globulin SC, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "immune globulin SC decreases effects of BCG vaccine live by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efgartigimod alfa",
            "description": {
                "common": "efgartigimod alfa will decrease the level or effect of immune globulin SC by  receptor binding competition. Use Caution/Monitor. Coadministration of efgartigimod with medications that bind to the human neonatal Fc receptor may lower systemic exposures and effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. If long-term use of such medications is essential, consider discontinuing efgartigimod and using alternative therapies."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles (rubeola) vaccine",
            "description": {
                "common": "immune globulin SC decreases effects of measles (rubeola) vaccine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "immune globulin SC decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "immune globulin SC decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rubella vaccine",
            "description": {
                "common": "immune globulin SC decreases effects of rubella vaccine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "immune globulin SC decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "immune globulin SC decreases effects of varicella virus vaccine live by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethotoin",
            "description": {
                "common": "ethotoin, immune globulin SC. Mechanism: unknown. Minor/Significance Unknown. Risk of hypersensitivity myocarditis (theoretical interaction, based on IM and IV immune globulin)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin, immune globulin SC. Mechanism: unknown. Minor/Significance Unknown. Risk of hypersensitivity myocarditis (theoretical interaction, based on IM and IV immune globulin)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin, immune globulin SC. Mechanism: unknown. Minor/Significance Unknown. Risk of hypersensitivity myocarditis (theoretical interaction, based on IM and IV immune globulin)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "protein a column",
            "description": {
                "common": "protein a column decreases levels of immune globulin SC by Other (see comment). Minor/Significance Unknown. \nComment: Since Prosorba binds IgG, it could theoretically interfere with the levels and/or effects of pharmacologic immune globulins."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Infusion reactions",
            "percent": null
        },
        {
            "name": "Allergic",
            "percent": null
        },
        {
            "name": "anaphylactic reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "swollen face",
            "percent": null
        },
        {
            "name": "tongue and pharyngeal edema",
            "percent": null
        },
        {
            "name": "pyrexia",
            "percent": null
        },
        {
            "name": "chills",
            "percent": null
        },
        {
            "name": "dizziness",
            "percent": null
        },
        {
            "name": "hypertension",
            "percent": null
        },
        {
            "name": "changes in blood pressure",
            "percent": null
        },
        {
            "name": "malaise",
            "percent": null
        },
        {
            "name": "tachycardia",
            "percent": null
        },
        {
            "name": "flushing",
            "percent": null
        },
        {
            "name": "Cardiovascular",
            "percent": null
        },
        {
            "name": "Chest discomfort",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "chest pain",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Neurological",
            "percent": null
        },
        {
            "name": "Tremor",
            "percent": null
        },
        {
            "name": "burning sensation",
            "percent": null
        }
    ]
}